Nevro Spinal Cord Stimulators

Seventeen federal cases against Nevro Corp. are pending across six districts, with oral arguments on MDL consolidation scheduled for September 24, 2026. The U.S. Judicial Panel on Multidistrict Litigation declined on June 5, 2026, to fold Nevro cases into the industry-wide Boston Scientific MDL (MDL-3181, Judge Josephine L. Staton, C.D. Cal.), leaving Nevro-specific litigation to proceed separately. Core allegations target the Senza, Senza II, Senza Omnia, HFX, and HFX iQ systems for defective design, failure to warn, and manufacturing deviations from FDA-approved specifications.

Nevro spinal cord stimulator litigation awaits JPML consolidation ruling after September 24, 2026 oral arguments on proposed MDL 3195. Seventeen federal cases currently pend across six districts; Nevro formally opposes consolidation, arguing cases lack common defects. No transferee court or judge assigned.

Nevro reports its 10 kHz Therapy has impacted more than 80,000 patients globally as of October 2022. Devices involved: Senza, Senza II, HF10/HFX, HFX iQ, Senza Omnia. Reported complications include lead migration, lead fracture, infection, neurological injury, syncope, incontinence, loss of pain relief, undesirable stimulation changes, and explantation. No MDL or settlement; state SOL windows govern filing deadlines.

• Louisiana

  Greene v. Nevro Corp., 3:23-cv-01648 (M.D. La. Jan. 31, 2025), Judge John W. deGravelles. Plaintiff Ashley Greene alleges permanent nerve damage, loss of mobility, and inability to live independently following implantation of Nevro spinal cord stimulator by neurosurgeon Charles Bowie, M.D. Court granted Nevro's motion to dismiss with leave to amend; plaintiff given 28 days to plead parallel federal violation to avoid preemption under Medical Device Amendments.

• New Mexico

  Yusnukis v. Nevro Corp., 1:24-cv-00355 (D.N.M. Feb. 24, 2026), Judge Sarah M. Davenport/Magistrate Judge Jerry F. Rael. Plaintiff Ron Yusnukis alleges syncopal episodes and incontinence from Nevro Omnia SCS, explanted after 49 days. Court granted dismissal: manufacturing defect and implied warranty claims preempted; parallel federal violation claims not plausibly pled. Device implanted March 2021.

• N.D. California

  First Nevro lawsuits filed March 23, 2026. Part of 17 federal cases pending across six districts as of September 2026. Proposed MDL 3195 hearing before JPML scheduled September 24, 2026.

• Costa Rica (manufacturing)

  Nevro FDA-approved manufacturing facility in Coyol Free Trade Zone, Alajuela, Costa Rica, operational since October 2022. Produces Senza, Senza II, and HFX platform devices for global distribution. FDA approval announced October 4, 2022.

• Nationwide (proposed MDL)

  17 federal Nevro cases pending across six districts as of September 22, 2026. JPML oral arguments September 24, 2026 on proposed MDL 3195. Nevro formally opposed consolidation August 6, 2026, arguing cases lack common defects. No MDL established; no settlement or global fund exists.

Nevro SCS claims depend on state product-liability statutes, implant/explant dates, symptom onset, discovery of device causation, and tolling agreements. The JPML petition specifically flags a tolling agreement through August 1, 2026 for movants’ counsel, but that may not protect every claimant.